Time to climb aboard!
Well it held @ .04 for a while before it came down to these levels and that was before getting approved so hopefully we see .10+ after approval.
Agree , volume is good and price appreciation on the table . How far will this go with positive results?
Certainly no reason to sell, just got to look at past history to see this will run upto FDA news, and this time it looks like company has completed everything and more FDA requested.
This is great news! I can't wait to see this finally get full accepted with FDA! Good luck to everyone who has stuck it out!
Your delusional as well. Did you miss a decimal point genius
That would make the market cap $187.6 Billion. Nice. KInd of unlikely.
You are an idiot if you shred the FDA drug approval calendar… do some actual research it’s a 510k application that will be submitted… not a drug but a medical device… I can go in and on about the potential on this one… the last hurdle is final testing then FDA approval and the fun begins!
It's amazing how these companies could push the same scam year after year. The first thing I looked for was RMSL. Nothing. So I will educate you, people, to know when you are being lied to. This stock can rest in peace now
I believe there is a reason they moved to OTCQB
New tweet from Remsleep;
RMSL is pleased to announce that it has finalized the design and commissioned the tooling for a disposable version of the DeltaWave - initial designation LifeGuard. The LifeGuard has the potential to treat COPD and CH patients in
Institutions and at home. The company also has 2 design patents, and a CIP
pending. One should issue shortly. The company has run into a delay with the cytoxicity testing. There is one component of the DeltaWave that requires a retest. We now expect testing to be finalized by the end of May. This retest was unexpected, disappointing to all. We are
not expecting any further delays. We remain committed to the goal of bringing the
DeltaWave to market at the earliest opportunity”
What does this have to do with RMSL specifically? Remsleep had no part in this. It was those two bozos which did this with multiple stocks.
Tampa, FL, January 6, 2023 — McapMediaWire — RemSleep Holdings Inc. (OTCQB: RMSL), a medical device manufacturer dedicated to forever changing the level of treatment provided to obstructive sleep apnea patients, today provides a corporate update and letter to shareholders from CEO Tom Wood.
Dear RemSleep Shareholders,
2023 is shaping up to be an extremely pivotal year for RemSleep and I couldn’t be more excited for the Company due to how we are currently positioned going into the New Year. We have several key priorities, goals, and product updates that I’d like to share with our investors as we look out into the next six months.
Our first and primary goal is a successful 510K submission for the DeltaWave CPAP mask. As stated in previous press releases, we hired an extremely qualified Senior Director for Regulatory Compliance and Regulatory Submission in Judy Strzepek. Her prior experience, collaboration with our new testing partner (who specializes in respiratory class II medical device testing, cleaning, and validation), and expertise with the FDA procedures has already proven to be invaluable to the submission process. We successfully completed a key meeting with the FDA last month which reaffirmed our testing criteria, testing execution, and remaining testing plan going forward. DeltaWave testing remains on track and is expected to be completed by mid-February to mid-March. Upon completion, we plan on immediately submitting our finalized FDA 510k submission. On a separate but related note, we are excited to announce our next generation masks, servicing both consumer and institutional (hospital, clinics, nursing homes, etc.) markets, could be on the market much sooner than originally anticipated due to the regulatory guidance provided by Ms. Strzepek. Once the current version of DeltaWave is cleared by the FDA, RemSleep will now have a quicker pathway to clearance for subsequent generations of DeltaWave based on their functionality or changes made to the original version. This will result in saving the company significant time and money in the clearance process as well as getting these products to market.
In conjunction with our confidence in the 510K process, the company is ramping up its sales and marketing plan for the release of the patented DeltaWave mask and next generation masks. This plan includes: adding additional in house and 3rd party resources to further develop this plan and launch these products; evaluating and further developing existing distributor and industry partners for a successful, commercial launch; naming of the new, next generation products, as well as some yet to be announced products, so all remain consistent with the RemSleep branding; and finally, adding professional sales executives with product launch & industry experience. Prioritizing this plan in the first quarter will help ensure a successful, broad market launch of the DeltaWave and next generation products upon FDA clearance.
Business execution continues to be a constant priority. The Company remains in a healthy cash position and expects to have sufficient capital on hand to execute the business plan through the successful commercial launch of the aforementioned products. Please see our latest financial statements as filed with OTC Markets Group. Within the business execution realm, we have reassessed the CPAP inventory and initial sales plan and have pursued new sales channels to address this inventory and future sales. The CPAP industry had several key product recalls in a rather difficult time period where supply was already short and demand was soaring. While this created opportunity for immediate sales and exposure, it also created new concerns and hesitation for distributors and end users with respect to liability. We had a key customer, who represented a substantial volume of initial pre-sales for these CPAP machines, back out of an agreement as they waited for clarity from the industry concerning new approvals and regulations in light of the ongoing and/or developing recalls. The presold units thus became unexpected inventory. While a number of these units were subsequently sold to different customers, we carried significantly more inventory than planned and thus had to shift focus on new markets for these particular units. This issue is not unique to RemSleep and remains an ongoing, industry challenge. That being said, that shift in focus has created a new sales channel development and has restored our confidence in these CPAP sales. While it is too soon to formally announce this development, we will share it with investors as soon as it is prudent to do so from a regulatory and competitive, strategic standpoint. Besides the revenue impact for the Company, this shift of product out of inventory on the balance sheet will free up significant capital for the ongoing business execution through and past FDA clearance.
Finally, our next generation masks have shown strong, internal indications of relief from those suffering from Chronic Obstructive Pulmonary Disease (COPD) and/or Congestive Heart Failure (CHF) in conjunction with their sleep apnea. We plan to conduct formal, FDA clinical study/trials to prove efficacy of this relief from COPD and CHF. Currently, there are no sleep apnea/CPAP masks on the market with these multiple indications. Successful, clinical trials should give RemSleep a competitive advantage for a new market for traditional CPAP masks. Further, it will be a critical step in differentiating the superiority of RemSleep products in the marketplace and subsequently further the sales, marketability, and overall profitability of the RemSleep product lineup. From the beginning, the Company has had a goal of being acquired. This new market should dramatically enhance the overall value of RemSleep and sense of urgency to act for potential acquirers. We are currently evaluating potential hospitals and sleep centers for these future studies/trials.
We have come a long way through our successes and setbacks but we still have a lot of work to do. However, our path is clear and we will continue to focus on the business execution from here on out. There are additional goals and targets for the Company longer term, but let’s get through the FDA 510K process first and allow that clearance to continue to open doors for the Company. We continue to appreciate and value the input, patience, and loyalty from our shareholders. We have the right team in place, with the right products coming to the market at the right time, and a wonderful investor base. For those reasons, I am truly thankful and excited for this New Year. Now let’s get back to work!
I hope they throw the book at these scumbags!
C. The REMSleep Holdings, Inc. (“RMSL”) Stock Promotion Scheme
102. On December 13, 2019, Costello acquired over 4.5 million shares of RMSL, and its stock closed at $0.02 that day. Costello purchased an additional 121,000 shares of RMSL on the morning of December 16.
103. Also on the morning of December 16, Costello messaged Ferraro to share his position: “RMSL. In for 4 mil total.” Ferraro replied that he would “start researching for noon so I have a story to tell.”
104. At 10:57 a.m. on December 16, Ferraro tweeted: “T minus 1 hour and 4 minutes....”
105. At noon, referencing a predicted 1,000 percent gain, Ferraro tweeted: “And the huge 10 bagger is....... $RMSL !!!!!!!!!!!!!!!!!!!!!!! $RMSL has entered the VERY LUCRATIVE Sleep apnea medical device market!!! They put out PR’s regularly. They should have a market cap over $10M!!! The chart is screaming for a massive run up!!!!”
106. Ferraro ultimately posted at least 100 tweets on December 16 and over 200 additional tweets over the next two weeks promoting RMSL. RMSL’s stock price reached an intraday high of $0.0368 on December 16 and closed at $0.031 that day, a 55 percent increase over the prior day’s close.
107. At no point did Costello or Ferraro disclose that Costello was selling RMSL stocks during this time period or that Ferraro would receive a share of Costello’s profits.
108. Costello began selling his shares of RMSL shortly after Ferraro began tweeting about RMSL on December 16, and sold his entire position by December 19 for profits of approximately $64,000. Costello shared $9,100 of those profits with Ferraro.
Posters claiming DeltaWave is the first mask to-treat-COPD-which-is-false. DeltaWave is not cleared in any capacity by the FDA and certainly not specifically to treat COPD and congestive heart failure. Any FDA cleared mask can and have already been be used by people with COPD. There is NO info from RMSL claiming DeltaWave is the first mask to treat COPD or congestive heart failure.
RMSL PR generally referencing that cpaps can be used to improve these issues:
Need $2millionRevenues/Quarter to break even. S-1 will be-re-filed-within-a-year.
Yes but the gross margin on those machines is only 25% and they are burning through 1/2 million in cash per quarter for operating expenses. Costs are going to go up with the additional testing required and the hiring of Judy for the new classification.
Not sustainable without dilution at some point.
Did you forget about the 1.2 million in inventory. Company had just purchased a lot of CPAP machines to sell.
Accumulated deficit increased by $440k from $10.7 million to $11.15 million.
Won't be too long before that S1 is re-filed.
Link to DeltaWave new patent application #17/215,589, continuation-of-15/595,990 (now Pat No. 10,987,481)
REMSleep Holdings, Inc. is engaged in the business of developing and distributing sleep apnea products. The Company focuses on offering optimum compliance and comfort for continuous positive airway pressure (CPAP) patients. Its DeltaWave CPAP interface (the DeltaWave) is a device to treat patients with sleep apnea. Its DeltaWave product is a nasal-pillows type interface that is designed with airflow characteristics to enable patients with sleep apnea to breathe normally. Its product is manufactured by mold makers. Its target market includes home care dealers, private sleep labs, product end users, sleep physicians, medical groups, sleep product distributors, hospitals, medical associations, such as the American academy of sleep medicine and the American sleep association. REMSleep LLC is its wholly owned subsidiary.
Medical Equipment & Supplies
2202 N. WEST SHORE BLVD SUITE 200
Russell Finlay Bird
Chairman of the Board
Thomas J. Wood
Chief Executive Officer, Director
Jonathan B Lane
Chief Technology Officer, Vice President